IL2106

IL2106 (also designated IL-2106) is a preclinical-stage small molecule molecular glue degrader being developed by IlDong Pharmaceutical Co., Ltd. and its spin-off company iLeadBMS. The compound targets cyclin-dependent kinase 12 (CDK12) and acts as a Cyclin K degrader. IL2106 binds to the interface of CDK12 and selectively induces the degradation of Cyclin K through the body's ubiquitin-proteasome protein degradation mechanism. This targeted protein degradation (TPD) approach is being investigated for the treatment of solid tumors, with active preclinical research focusing on triple-negative breast cancer (TNBC), HER2-negative gastric cancer, and metastatic breast cancer. Preclinical studies presented at ESMO TAT 2024 demonstrated strong growth inhibition of TNBC and HER2-negative gastric cancer cells, with significant tumor size reduction and decreased cancer cell metastasis in animal models.